Login to Your Account

Epimab licenses 'druggable' bispecific technology to Innovent for $120M

By Shannon Ellis
Staff Writer

Tuesday, June 7, 2016

SHANGHAI – Epimab Biotherapeutics Inc.  inked its first licensing deal for its bispecific antibody platform technology to one of China's rising biopharma stars, Innovent Biologics Inc., of Suzhou.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription